Imlifidase

Name: Imlifidase in Kidney transplantation in highly sensitized patients: Generic, brand name and therapeutic class of product
Published: 2026-09-14T15:39:06-04:00

Kidney transplantation in highly sensitized patients

Manufacturer: Hansa Biopharma
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Generic, brand name and therapeutic class of product

2 evidence topics · 3 sources

Manufacturer: Hansa Biopharma

“Hansa Biopharma AB, (“Hansa” or “the Company”), (Nasdaq Stockholm: HNSA), today announced that its Biologics License Application (BLA) for imlifidase has been accepted” (opens the source at this quote in a new tab)

Product identity

“Idefirix contains the active substance imlifidase.” (opens the source at this quote in a new tab)